Giesen

Researchers are conducting a Phase 3, randomized, double-blind, multiregional study to compare two treatments for metastatic non-small cell lung cancer (NSCLC). The study includes two separate groups based on NSCLC histology: squamous and non-squamous types. The main goals are to evaluate overall survival and progression-free survival, with additional focus on treatment response and safety. Participants are randomly assigned to receive either ivonescimab combined with platinum-doublet chemotherapy or pembrolizumab combined with platinum-doublet chemotherapy. Both treatments are given as intravenous injections. Each histology group will be analyzed separately, with about 600 patients in the squamous group and 1000 in the non-squamous group. During the study, participants will be monitored for survival outcomes over approximately 3 to 4 years. Researchers will assess tumor response and safety through regular evaluations. Eligibility requires confirmed metastatic NSCLC, with specific tumor measurements and no prior systemic treatment for metastatic disease. This study aims to provide important information on these first-line treatment options for metastatic NSCLC.

Researchers are evaluating ivonescimab as a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors show high PD-L1 expression. This phase 3 randomized, double-blinded study compares ivonescimab with pembrolizumab to assess overall survival and progression-free survival in this patient group. Participants will receive either ivonescimab or pembrolizumab as intravenous injections. The study is designed to monitor these treatments over time to determine which may provide better outcomes in controlling metastatic NSCLC in patients with high PD-L1 levels. The study includes patients with measurable non-brain lesions and no prior systemic treatment for metastatic NSCLC. During the trial, patients will be closely followed for up to approximately 36 months to measure overall survival and progression-free survival. Researchers will assess the safety and effectiveness of the treatments through regular evaluations, including monitoring for disease progression and survival status. This long-term follow-up ensures comprehensive understanding of treatment impact over time.

Researchers are evaluating how well the drug cabozantinib works and how safe it is for adults with neuroendocrine tumors (NETs), a type of cancer that can occur in various parts of the body. This study focuses on participants whose cancer has continued to grow despite having received at least one previous systemic treatment. The study is conducted in regular hospitals and clinics in Germany and Austria, involving about 150 participants taking cabozantinib as part of their usual care. The study is observational, meaning no extra tests or procedures are performed beyond routine medical care. Participants receive cabozantinib treatment as decided by their doctors before joining the study. Researchers collect information from regular medical visits, tests, and scans to monitor how the cancer responds to the treatment and how long participants stay on cabozantinib. They also track any side effects and assess the impact of treatment on participants' quality of life. Participants are involved by attending their usual medical appointments where doctors gather data on their health and treatment progress. The main outcome measured is the Disease Control Rate (DCR) at 6 months. Safety is monitored through observations of side effects during regular care. The study duration depends on each participant's treatment course, with data collected throughout their time on cabozantinib.